Discover who’s speaking at Real-World Evidence 2020: Rare Diseases and Innovative Therapies

Pharmaphorum event posting banner

Don’t miss your chance to attend: 

Real-World Evidence 2020:
Rare Diseases and Innovative Therapies

1–2 April 2020 

1 America Square, London, UK 

Hosted by the Journal of Comparative Effectiveness Research and The Evidence Base®Real-World Evidence 2020: Rare Diseases and Innovative Therapies will convene stakeholders across the real-world evidence (RWE) ecosystem to explore the practical applications of RWE to rare diseases and next-generation treatments.  

Over 1–2 April, join distinguished expert Professor Karen Facey, Senior Research Fellow at the University of Edinburgh (UK) and Co-Lead Investigator of IMPACT-HTA, to hear leading national and international experts share their expertise and contribute to the RWE conversations that matter to you most. 

View the agenda now>> 

Specialist speakers include: 

  • Amanda Cole,Principal Economist, Office of Health Economics 
  • Charles Makin, Global Head Real-World Evidence Strategy, Biogen
  • Christian Hill, CEO, MAP BioPharma
  • Joanne Hackett, CCO, Genomics England
  • Panos Kefalas, Head of Health Economics and Market Access, Cell and Gene Therapy Catapult
  • Paolo Morgese, EU Director of Market Access and Member Relations, Alliance for Regenerative Medicine
  • Richard White, COO, Oxford PharmaGenesisLtd 

 We are also thrilled to announce that our confirmed keynote speaker is the multi-Michelin Star, award-winning chef, Jean-Christophe Novelli! 

There are limited tickets available, so book quickly to join the industry’s first European RWE event solely focused on rare diseases and innovative therapies.  

Book now>>

For more information, visit, or for information on partnering and sponsorship, please contact Luke Raphael at or +44(0) 794 1000110.

The Evidence Base

The Evidence Base

21 February, 2020